Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Bayer : helping people affected by the earthquake in Mexico

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CEST

Release date- 29092017 - Leverkusen - As part of its disaster relief program, Bayer is donating medicines worth EUR 268,000 to the victims of the major earthquake that struck Mexico.

This aid will offer speedy and unbureaucratic relief to the people affected by this tragedy in Central America. The medicines will be sent to the non-profit organization Direct Relief for distribution to people injured in the quake. Direct Relief is a long-term strategic partner of Bayer that provides assistance and medical supplies around the world to regions torn by crisis and areas with limited medical access. Mexico City was hit by a magnitude 7.1 earthquake on September 19, 2017, and hundreds of people perished.

Providing disaster relief is part of Bayer's social commitment. The company follows a dual strategy to help people affected by acute hardship: When disaster strikes, Bayer provides immediate assistance - either by donating money and medicines or making material donations to help rebuild infrastructure. In addition, Bayer AG's charitable foundation, the Bayer Cares Foundation, supports long-term reconstruction projects.

In 2017, Bayer has already provided support to projects in the following nine regions affected by disasters: The Brazilian organization Mundo Positivo received a donation of EUR 203,000 to implement a preventive program in the state of Pernambuco, which has been hit by the Zika virus. The Canadian Red Cross received EUR 14,000 to combat devastating wildfires in rural areas. The organization Direct Relief and the American Red Cross received EUR 93,000 each to provide rapid assistance to people in the U.S. state of Texas, one of the areas hit by Hurricane Harvey. The Chilean fire service received EUR 92,000 to initiate a family protection program. Medicines were donated to the CDC Foundation for distribution to young women attending prenatal visits in Puerto Rico, one of the countries affected by the Zika virus (worth EUR 56,000); the Colombian Civil Air Patrol to assist people affected by flooding in Mocoa (EUR 24,000) and U.S. animal welfare organizations to help care for pets and livestock injured by Hurricane Harvey (EUR 24,000). The Nigerian Ministry of Agriculture also received plant protection products worth EUR 30,000 for smallholder farmers to use to treat crops infested with armyworm moths. In total, ten projects have now received donations of money or products totaling around EUR 897,000.

Bayer Cares Foundation

As the social welfare foundation of the innovation company Bayer, the Bayer Cares Foundation sees itself especially as an initiator, promoter and partner for innovation at the interface between industry and the social sector. The sponsorship programs are focused on people - their commitment to public welfare, their wealth of ideas in fulfilling social needs, as well as those that arise in times of emergency. The foundation's funding activities are a central element of Bayer's global social commitment amounting to approximately EUR 50 million annually - with the focus on promoting scientific education and leading-edge research, and on providing health care and meeting the basic social needs of people who live near the company's sites.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contact:

Tel: +49 214 30-39239

Fax: +49 214 30-58923

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
01:29aBAYER : Financial Risk Management Software Market valued at US$ 7.04 billion in ..
AQ
01:22aBAYER : Dental Drugs Market valued at US$ 4.25 Mn in 2017 and is expected to rea..
AQ
06/22BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/22BAYER : Demonstrates Its Commitment to Human Rights
AQ
06/21BAYER : Findings from Bayer Update Understanding of Cardiovascular Agents (Clini..
AQ
06/21BAYER : Recent Findings from Bayer Provides New Insights into Chemical Modeling ..
AQ
06/21STUDY DATA FROM BAYER UPDATE UNDERST : A Small-Molecule Oral HIF-Prolyl Hydroxyl..
AQ
06/21BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/21BAYER : Issues New Bonds With a Volume of 15 Billion U.S. Dollars
AQ
06/21BAYER : supports a new UN code opposing discrimination against lesbian, gay, bis..
PU
More news
News from SeekingAlpha
06/21American Vanguard buys Bromacil herbicide assets from Bayer 
06/20SA INTERVIEW : Chris DeMuth Jr. On First United And ETF Reconstitutions 
06/19Can-Fite up 14% premarket on encouraging mid-stage Namodenoson data 
06/13Biotech industry group criticized for party featuring topless dancers 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
Financials (€)
Sales 2018 39 085 M
EBIT 2018 7 631 M
Net income 2018 5 385 M
Debt 2018 32 174 M
Yield 2018 2,88%
P/E ratio 2018 18,32
P/E ratio 2019 17,04
EV / Sales 2018 3,14x
EV / Sales 2019 2,56x
Capitalization 90 364 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 116 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-5.82%105 076
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862